Vande Casteele, Niels http://orcid.org/0000-0003-0854-0274
Oyamada, Jun
Shimizu, Chisato
Best, Brookie M.
Capparelli, Edmund V.
Tremoulet, Adriana H.
Burns, Jane C.
Article History
First Online: 5 April 2018
Compliance with Ethical Standards
:
: No funding was received for any part of the development and publication of the manuscript. The study by Burns et al. was supported by a grant from Centocor, Inc. and the National Institute for Child Health and Human Development, Pediatric Pharmacology Research Unit (PPRU) Network (5U10HD031318). Centocor Inc. performed the determinations of infliximab levels and the assays for anti-infliximab antibodies. The study by Tremoulet et al. was supported in part by an FDA Orphan Drug grant (FD 003514) awarded to JCB, and a Robert Wood Johnson Foundation grant awarded to AHT. Janssen Biotech, the manufacturer of infliximab, provided commercial-grade drug for this study.
: Niels Vande Casteele has received consultancy fees from Janssen outside of the submitted work. Jun Oyamada, Chisato Shimizu, Brookie M. Best, Edmund V. Capparelli, Adriana H. Tremoulet, and Jane C. Burns have no conflicts of interest to declare.